Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 04, 2019 07:00 ET | Source: Prevail Therapeutics

Prevail Therapeutics to Present at Morgan Stanley 2019 Global Healthcare Conference

NEW YORK, Sept. 04, 2019 (GLOBE NEWSWIRE) -- Prevail Therapeutics Inc. (Nasdaq: PRVL) (“Prevail” or “the Company”), a biotechnology company developing potentially disease-modifying AAV-based gene...
August 14, 2019 07:00 ET | Source: Prevail Therapeutics

Prevail Therapeutics Reports Second Quarter 2019 Financial Results and Recent Business Highlights

IND Active for Phase 1/2 Trial of PR001 to Treat Parkinson’s Disease Patients with GBA1 Mutations Successful $125.0 Million Initial Public Offering Completed to Support Program Advancement and...
August 07, 2019 16:00 ET | Source: Prevail Therapeutics

Prevail Therapeutics to Present at 2019 Wedbush PacGrow Healthcare Conference

NEW YORK, Aug. 07, 2019 (GLOBE NEWSWIRE) -- Prevail Therapeutics Inc. (Nasdaq: PRVL) (Prevail), a biotechnology company developing potentially disease-modifying AAV-based gene therapies for patients...
July 08, 2019 08:00 ET | Source: Prevail Therapeutics

Prevail Therapeutics Receives U.S. FDA Fast Track Designation for PR001 for the Treatment of Parkinson’s Disease Patients with a GBA1 Mutation

NEW YORK, July 08, 2019 (GLOBE NEWSWIRE) -- Prevail Therapeutics Inc. (Nasdaq: PRVL) (Prevail), a biotechnology company developing potentially disease-modifying AAV-based gene therapies for patients...